Compare LEG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEG | NTLA |
|---|---|---|
| Founded | 1883 | 2014 |
| Country | United States | United States |
| Employees | 15900 | N/A |
| Industry | Home Furnishings | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2018 | 2016 |
| Metric | LEG | NTLA |
|---|---|---|
| Price | $10.80 | $12.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 23 |
| Target Price | $10.50 | ★ $20.02 |
| AVG Volume (30 Days) | 3.7M | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 145.31 | 27.43 |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $5,203,900,000.00 | $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.73 | $62.75 |
| P/E Ratio | $6.54 | ★ N/A |
| Revenue Growth | 1.37 | ★ 16.92 |
| 52 Week Low | $7.86 | $6.83 |
| 52 Week High | $13.00 | $28.24 |
| Indicator | LEG | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 40.61 |
| Support Level | $9.28 | $11.19 |
| Resistance Level | $11.94 | $14.71 |
| Average True Range (ATR) | 0.48 | 1.18 |
| MACD | -0.00 | -0.27 |
| Stochastic Oscillator | 40.25 | 11.03 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the maximum of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.